About: Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019
Creator	Wampler Muskardin, Theresa
Source	Medline; PMC
abstract	Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) are increasingly recognized as being on a continuum of cytokine storm syndromes, with different initiating pathways culminating in cytotoxic dysfunction and uncontrolled activation and proliferation of T lymphocytes and macrophages. The activated immune cells produce large amounts of proinflammatory cytokines, including interleukin 1β (IL)‐1β. Management depends on the recognized diagnosis. In the setting of a cytokine storm syndrome and infection, collaborative involvement of specialists, including infectious disease and rheumatology is ideal. Anakinra, a recombinant IL‐1 receptor antagonist, has been used subcutaneously and intravenously in pediatric patients and is considered a first‐line treatment for MAS and secondary HLH (sHLH) among many pediatric rheumatologists. Previous reports of anakinra used in adults for treatment of MAS or sHLH are limited to subcutaneous administration. In this issue, Moneagudo et al. present a series of adult patients with sHLH treated with intravenous anakinra, including patients in whom subcutaneous anakinra was insufficient. As the authors suggest, there is a potential therapeutic use for anakinra in sHLH or the cytokine storm syndrome triggered by COVID19. Trial design will be key, with the patient subpopulation, timing of intervention, and doses tested important.
has issue date	2020-05-10(xsd:dateTime)
bibo:doi	10.1002/acr2.11140
bibo:pmid	32267072
has license	cc-by-nc
sha1sum (hex)	3cf5a995f1004021d8280508ce5e582f58b80cd5
schema:url	https://doi.org/10.1002/acr2.11140
resource representing a document's title	Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019
has PubMed Central identifier	PMC7231517
has PubMed identifier	32267072
schema:publication	ACR Open Rheumatol
resource representing a document's body	covid:3cf5a995f1004021d8280508ce5e582f58b80cd5#body_text
is schema:about of	named entity 'Macrophage' named entity 'Macrophage Activation Syndrome' named entity 'cytokine storm' named entity 'subcutaneously' named entity 'MAS' named entity 'immune cells' named entity 'sHLH' named entity 'FDA' named entity 'MAS' named entity 'autoinflammatory disease' named entity 'HLH' named entity 'rheumatic disease' named entity 'virus' named entity 'genetic testing' named entity 'sHLH' named entity 'HLH' named entity 'HLH' named entity 'periodic fever syndrome' named entity 'IL-1β' named entity 'autoimmune' named entity 'HLH' named entity 'COVID19' named entity 'pediatric' named entity 'infection' named entity 'double-blind, placebo-controlled' named entity 'anakinra' named entity 'sHLH' named entity 'inflammation' named entity 'rheumatologists' named entity 'infection' named entity 'HLH' named entity 'blocking antibody' named entity 'immunosuppressive' named entity 'sHLH' named entity 'anakinra' named entity 'COVID19' named entity 'anakinra' named entity 'IL-6' named entity 'anakinra' named entity 'intravenous' named entity 'lungs' named entity 'IV administration' named entity 'cytotoxic' named entity 'COVID19' named entity 'sHLH' named entity 'Immunotherapy' named entity 'Cytokine' named entity 'emapalumab' named entity 'lymphocyte' named entity 'SARS-CoV-2' named entity 'adverse effect' named entity 'superinfections' named entity 'sHLH' named entity 'respiratory failure' named entity 'emapalumab' named entity 'cytokine storm syndrome' named entity 'anakinra' named entity 'first-line treatment' named entity 'sHLH' named entity 'subcutaneous administration' named entity 'infection' named entity 'monogenic' named entity 'tropism' named entity 'lymphocytes' named entity 'Regeneron' named entity 'cryopyrin' named entity 'mortality rate' named entity 'infection' named entity 'anakinra' named entity 'Anakinra' named entity 'MAS' named entity 'IV administration' named entity 'sHLH' named entity 'sHLH' named entity 'HLH' named entity 'first-line treatment' named entity 'hematology/oncology' named entity 'sHLH' named entity 'IL-1' named entity 'anakinra' named entity 'microbial'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software